The problem
Cancer patients fall through the cracks between appointments, and plans pay for avoidable ER visits
What they do
Value-based cancer care navigation for health plans, employers and oncology practices
Traction 2025 revenue $125M+, 5x 2024; profitable; 10K to 135K patients since end of 2024
Hiring trend
- Open roles
- 52
- Ops roles
- 3
- Headcount
- ~670
Headcount ~150 (2023) to ~669 (Mar 2026), Revelio est.; 52 open roles, almost all remote
Hiring in
- New York
- Remote
Glassdoor
3.1 ★ 96 reviews ↗Funding
- Last round
- $125M+
- Stage
- Series E
- Date
- Sep 2026
Led by Morgan Health (with Humana, CVS Health Ventures)
- Hiring+252 open roles on the live job board (30+ roles = +2)
- Funding recency+2Series E · $125M+, Sep 2026 (1 month ago): 6 months or less = +1.5, $100M+ round +0.5
- Traction+1.5Strong growth: 2025 revenue $125M+, 5x 2024; profitable; 10K to 135K patients since end of 2024
- Red flags0None found in the last 24 months
- Total5.52 + 2 + 1.5 − 0 = 5.5 → Sprint (4.75 or more)
Distance (Half) is a separate read on how long the lead can last. It doesn't change the score.
Distance
Half · edge: grows with users
Leading value-based oncology navigator: $7B+ oncology spend managed, 10.5M covered lives, valuation doubled to $2B+.
Sources: Tech Funding News: Thyme Care doubles valuation to $2B+ (Sep 2026) ↗ · PR Newswire: Thyme Care closes $125M+ Series E (Sep 2026) ↗
Last checked Oct 25, 2026